leukotriene

[loo″ko-tri´ēn]

any of a group of compounds derived from unsaturated fatty acids, primarily arachidonic acid, that are extremely potent mediators of immediate hypersensitivity reactions and inflammation, producing smooth muscle contraction, especially bronchoconstriction, increased vascular permeability, and migration of leukocytes to areas of inflammation. Certain leukotrienes are collectively known as SRS-A (slow reacting substance of anaphylaxis), the name given to their potent bronchoconstrictor activity 30 years before their structure was elucidated; they also cause leakage of fluid and proteins from the microvasculature.

leukotriene

(lo͞o′kə-trī′ēn)

Any of several lipid compounds that contain 20 carbon atoms, are related to prostaglandins, and mediate the inflammatory response.

Mentioned in

References in periodicals archive

Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.

Montelukast reduces seizures in pentylenetetrazol-kindled mice

Comparison of therapeutic values between leukotriene receptor antagonist (montelukast) and inhaled glucocorticoid (beclomethasone propionate) in bronchial asthma of adults.

Effectiveness and Quality of Life with Montelukast in Asthma - A double-blind randomized control trial

Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma: a multicenter, randomised, doubleblind trial.

Protective Effects of Montelukast Against Stress-Induced Degeneration of the Urinary Bladder/Stres ile Uyarilmis Mesane Hasarina Karsi Montelukastin Koruyucu Etkileri

"At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage," Dr.

Researchers Reverse Cognitive Impairments in Mice with Dementia

Capra, "Molecular and functional aspects of human cysteinyl leukotriene receptors," Pharmacological Research, vol.

Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases

Authors stated previous research that "Prostaglandin E2 is involved in the classic signs of inflammation and possesses both pro-inflammatory and anti-inflammatory actions; thromboxane A2, formed by platelets, macrophages and polymorphonuclear leukocytes, can induce vasoconstriction and promotes aggregation of platelets as well as adhesiveness of polymorphonuclear neutrophils; leukotriene B4 (LTB4) can not only increase vascular permeability and enhance local blood flow by stimulating neutrophil secretion, but also stimulate other inflammatory substances."

Meta-analysis affirms association between omega-3 and lowered inflammation

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid: The Tokyo Joshi-Idai Asthma Research Group.

Comparative evaluation of moderate dose inhalational corticosteroid (ICS) fluticasone with the combination of low dose fluticasone and montelukast in moderate persistent bronchial asthma

[10] Patients were excluded if they had significant co-morbidities, were receiving oral corticosteroids, LABAs, leukotriene antagonists or theophylline or had undergone an asthma exacerbation or lower respiratory tract infection within the four weeks prior to study entry.

Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma

There has been interest in whether leukotriene modifiers may have a role in the management of COPD, although data have been relatively limited [127].

Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function

On the other hand, women were significantly more adherent than men were for leukotriene modifiers (0.499 vs.

Asthma med adherence: men inhale, women take pills